PMID- 18562414
OWN - NLM
STAT- MEDLINE
DCOM- 20091104
LR  - 20221207
IS  - 0269-8811 (Print)
IS  - 0269-8811 (Linking)
VI  - 23
IP  - 7
DP  - 2009 Sep
TI  - Neuroendocrine and subjective responses to pharmacological challenge with 
      citalopram: a controlled study in male and female ecstasy/MDMA users.
PG  - 759-74
LID - 10.1177/0269881108092336 [doi]
AB  - Despite evidence that +/-3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy') 
      causes persistent alterations to the serotonergic system of animals, evidence for 
      long-term neurological effects of ecstasy/MDMA in humans remains equivocal. The 
      current study assessed serotonin functioning of nine male and 11 female 
      recreational ecstasy polydrug users by measuring neuroendocrine (prolactin, 
      cortisol) responses to pharmacological challenge with the selective serotonin 
      reuptake inhibitor citalopram, compared with nine male and five female cannabis 
      polydrug users and 11 male and 11 female non-drug using controls. A single-blind, 
      randomised, placebo-controlled design was used. Subjective responses, other 
      substance use, mood, personality traits and demographic variables were measured 
      to control for potentially confounding variables. There were no significant 
      differences between ecstasy polydrug users, cannabis polydrug users and non-drug 
      using controls in neuroendocrine or subjective responses to serotonergic 
      challenge, and there were no sex by drug group interactions. There was no 
      relationship between extent of ecstasy use and neuroendocrine functioning, alone 
      or in combination with potential confounding variables. Subjective responses to 
      the pharmacological challenge (nausea, tremor, dry mouth), novelty seeking and 
      lifetime dose of alcohol were the only variables that contributed to one or more 
      of the neuroendocrine outcome variables. These data do not support the premise 
      that recreational ecstasy/MDMA use results in measurable impairment of 
      serotonergic control of endocrine activity.
FAU - Allott, K
AU  - Allott K
AD  - School of Psychology, Psychiatry and Psychological Medicine, Monash University, 
      Melbourne, Victoria, Australia. kallott@unimelb.edu.au
FAU - Canny, B K
AU  - Canny BK
FAU - Broadbear, J H
AU  - Broadbear JH
FAU - Stepto, N K
AU  - Stepto NK
FAU - Murphy, B
AU  - Murphy B
FAU - Redman, J
AU  - Redman J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20080618
PL  - United States
TA  - J Psychopharmacol
JT  - Journal of psychopharmacology (Oxford, England)
JID - 8907828
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 0DHU5B8D6V (Citalopram)
RN  - 9002-62-4 (Prolactin)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - Adult
MH  - Affect/drug effects
MH  - Cannabis/adverse effects
MH  - Citalopram/*pharmacology
MH  - Drug Users/*psychology
MH  - Female
MH  - Humans
MH  - Hydrocortisone/*blood
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*adverse effects
MH  - Personality/drug effects
MH  - Prolactin/*blood
MH  - Selective Serotonin Reuptake Inhibitors/*pharmacology
MH  - Sex Characteristics
EDAT- 2008/06/20 09:00
MHDA- 2009/11/05 06:00
CRDT- 2008/06/20 09:00
PHST- 2008/06/20 09:00 [pubmed]
PHST- 2009/11/05 06:00 [medline]
PHST- 2008/06/20 09:00 [entrez]
AID - 0269881108092336 [pii]
AID - 10.1177/0269881108092336 [doi]
PST - ppublish
SO  - J Psychopharmacol. 2009 Sep;23(7):759-74. doi: 10.1177/0269881108092336. Epub 
      2008 Jun 18.